Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.

Tofacitinib may help regrow hair in alopecia areata patients.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Enhancing Tregs can protect against alopecia areata.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Granzyme B is important in autoimmune skin diseases and could be a new treatment target.

Tofacitinib may help treat hair loss in children with alopecia areata.

Etanercept effectively treated a severe skin condition when other treatments failed.

Denosumab may cause alopecia areata.

A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.

Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.

Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.